The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride
최용혁, 조성용, 조인래,
소속 상세정보
최용혁 ( Choi Yong-Hyuk )
인제대학교 의과대학 비뇨기과학교실
조성용 ( Cho Soung-Yong )
인제대학교 의과대학 비뇨기과학교실
조인래 ( Cho In-Rae )
인제대학교 의과대학 비뇨기과학교실
KMID : 0358320100510100704
Abstract
PurposeTo compare and analyze the therapeutic effects and changes in the prostate-specific antigen (PSA) level with treatment with finasteride or dutasteride for benign prostatic hyperplasia (BPH) for 1 year.
Materials and MethodsWe retrospectively investigated patients who suffered from BPH for 1 year between January 2005 and December 2008. For treatment groups, we divided the patients into two groups: one was treated with alfuzosin and finasteride and the other was treated with alfuzosin and dutasteride. At the beginning of treatment, the patients underwent transrectal ultrasonography and measurement of urine flow rate, residual urine volume, PSA, and International Prostate Symptom Score (IPSS). Patients with diseases affecting urinary function were excluded. We not only analyzed the data at the time of initial treatment, but also after 1 year of treatment. A total of 219 patients were able to be evaluated for 1 year.
ResultsBoth finasteride and dutasteride reduced PSA and prostate volume significantly. The comparison between groups showed a more significant reduction of PSA (p=0.020) and prostate volume (p=0.052) in the dutasteride group. Other parameters did not differ significantly between the groups.
Conclusions5-α Reductase inhibitors for BPH treatment reduced PSA and prostate volume significantly when the patients were treated for 1 year. Administration of dutasteride is considered to be more effective in reducing PSA and prostate volume. Therefore, dutasteride should not be considered equivalent to finasteride in the reduction rate of PSA. The intensity of dutasteride must be reevaluated in comparison with finasteride.
키워드
Dutasteride;Finasteride;Prostate-specific antigen;Prostatic hyperplasia
원문 및 링크아웃 정보
등재저널 정보